{
 "companyname": "CYCLACEL PHARMACEUTICALS, INC.",
 "symbol": "CYCC",
 "description": "Pharmaceutical Preparations",
 "quarters": [
  {
   "cik": "0001130166",
   "companyname": "CYCLACEL PHARMACEUTICALS, INC.",
   "entityid": 81814,
   "primaryexchange": "Nasdaq Global Market",
   "primarysymbol": "CYCC",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "11/12/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "9/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 3,
   "dcn": "0001571049-15-009197",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": -615000,
   "changeincurrentliabilities": -1005000,
   "changeininventories": null,
   "dividendspaid": -50000,
   "effectofexchangerateoncash": -228000,
   "capitalexpenditures": -10000,
   "cashfromfinancingactivities": 170000,
   "cashfrominvestingactivities": -10000,
   "cashfromoperatingactivities": -4106000,
   "cfdepreciationamortization": 55000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": null,
   "netchangeincash": -4174000,
   "totaladjustments": -1397000,
   "ebit": -3394000,
   "costofrevenue": null,
   "discontinuedoperations": 0,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 715000,
   "incomebeforetaxes": -3187000,
   "interestexpense": null,
   "netincome": -2709000,
   "netincomeapplicabletocommon": -2759000,
   "researchdevelopmentexpense": 2904000,
   "totalrevenue": 715000,
   "sellinggeneraladministrativeexpenses": 1205000,
   "commonstock": 34000,
   "deferredcharges": null,
   "cashandcashequivalents": 22728000,
   "cashcashequivalentsandshortterminvestments": 22728000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": null,
   "othercurrentassets": 100000,
   "othercurrentliabilities": 75000,
   "otherequity": null,
   "otherliabilities": 186000,
   "preferredstock": 0,
   "propertyplantequipmentnet": 255000,
   "retainedearnings": -319785000,
   "totalassets": 27049000,
   "totalcurrentassets": 26794000,
   "totalcurrentliabilities": 5263000,
   "totalliabilities": 5449000,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": null,
   "totalstockholdersequity": 21600000,
   "treasurystock": null
  },
  {
   "cik": "0001130166",
   "companyname": "CYCLACEL PHARMACEUTICALS, INC.",
   "entityid": 81814,
   "primaryexchange": "Nasdaq Global Market",
   "primarysymbol": "CYCC",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "8/12/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "6/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 2,
   "dcn": "0001571049-15-006638",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": 2309000,
   "changeincurrentliabilities": -1953000,
   "changeininventories": null,
   "dividendspaid": -50000,
   "effectofexchangerateoncash": 452000,
   "capitalexpenditures": -8000,
   "cashfromfinancingactivities": -127000,
   "cashfrominvestingactivities": -8000,
   "cashfromoperatingactivities": -2778000,
   "cfdepreciationamortization": 50000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": null,
   "netchangeincash": -2461000,
   "totaladjustments": 569000,
   "ebit": -3617000,
   "costofrevenue": null,
   "discontinuedoperations": 0,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 296000,
   "incomebeforetaxes": -3752000,
   "interestexpense": null,
   "netincome": -3347000,
   "netincomeapplicabletocommon": -3397000,
   "researchdevelopmentexpense": 2580000,
   "totalrevenue": 296000,
   "sellinggeneraladministrativeexpenses": 1333000,
   "commonstock": 34000,
   "deferredcharges": null,
   "cashandcashequivalents": 26902000,
   "cashcashequivalentsandshortterminvestments": 26902000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": null,
   "othercurrentassets": 124000,
   "othercurrentliabilities": 75000,
   "otherequity": null,
   "otherliabilities": 198000,
   "preferredstock": 0,
   "propertyplantequipmentnet": 309000,
   "retainedearnings": -317076000,
   "totalassets": 30788000,
   "totalcurrentassets": 30479000,
   "totalcurrentliabilities": 6490000,
   "totalliabilities": 6688000,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": null,
   "totalstockholdersequity": 24100000,
   "treasurystock": null
  },
  {
   "cik": "0001130166",
   "companyname": "CYCLACEL PHARMACEUTICALS, INC.",
   "entityid": 81814,
   "primaryexchange": "Nasdaq Global Market",
   "primarysymbol": "CYCC",
   "siccode": "2834",
   "sicdescription": "Pharmaceutical Preparations",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "5/12/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "3/31/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 1,
   "dcn": "0001571049-15-004031",
   "currencycode": "USD",
   "crosscalculated": false,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": -1111000,
   "changeincurrentliabilities": 887000,
   "changeininventories": null,
   "dividendspaid": -50000,
   "effectofexchangerateoncash": -318000,
   "capitalexpenditures": -14000,
   "cashfromfinancingactivities": 10383000,
   "cashfrominvestingactivities": 9000,
   "cashfromoperatingactivities": -4900000,
   "cfdepreciationamortization": 52000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": null,
   "netchangeincash": 5174000,
   "totaladjustments": 12000,
   "ebit": -5298000,
   "costofrevenue": null,
   "discontinuedoperations": 0,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": 512000,
   "incomebeforetaxes": -5675000,
   "interestexpense": null,
   "netincome": -4912000,
   "netincomeapplicabletocommon": -4962000,
   "researchdevelopmentexpense": 4342000,
   "totalrevenue": 512000,
   "sellinggeneraladministrativeexpenses": 1468000,
   "commonstock": 34000,
   "deferredcharges": null,
   "cashandcashequivalents": 29363000,
   "cashcashequivalentsandshortterminvestments": 29363000,
   "goodwill": null,
   "intangibleassets": null,
   "inventoriesnet": null,
   "minorityinterest": null,
   "otherassets": null,
   "othercurrentassets": 147000,
   "othercurrentliabilities": 75000,
   "otherequity": null,
   "otherliabilities": 192000,
   "preferredstock": 0,
   "propertyplantequipmentnet": 333000,
   "retainedearnings": -313729000,
   "totalassets": 35357000,
   "totalcurrentassets": 35024000,
   "totalcurrentliabilities": 8136000,
   "totalliabilities": 8328000,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": null,
   "totalstockholdersequity": 27029000,
   "treasurystock": null
  }
 ]
}